The ability of modified low density lipoptoteins (LDLs) to induce both proliferation and death of endothelial cells is considered to be a mechanism of early atherosclerosis development. We have previously shown that carbamylated LDL (cLDL) induces human coronary artery endothelial cell (HCAEC) death in vitro. This effect is similar to the atherogenic action of oxidized LDL (oxLDL) that induces the proliferation and death of endothelial cells. The current study was designed to analyze a potential proliferative effect of cLDL and whether proliferation caused by modified LDLs is related to cell death. Cultured HCAECs were exposed to different concentrations of modified LDL or native LDL for varying periods of time. Cell proliferation measured by bromodeoxyuridine incorporation and S-phase analysis was dose-dependently increased in the presence of cLDL (6.25-200 µg/ml). The proliferation induced by cLDL or oxLDL was associated with cell death and increased phosphorylation of extracellular signal-regulated kinase (ERK) and Jun N-terminal kinase (JNK). Inhibition of the cLDLor oxLDL-induced proliferation by aphidicolin (1 µg/ml) was protective against both short-term cell death measured by lactate dehydrogenase release into the media, and long-term cell viability visualized by cell multiplication. Inhibition of ERK phosphorylation led to a significant decrease of DNA synthesis and cell rescue from injury by modified LDLs, while inhibition of JNK phosphorylation had an only partial rescue effect without involvement in cell proliferation. These data are the first evidence that endothelial cell death induced by cLDL or oxLDL is mediated by cell proliferation through the mitogenactivated protein kinase pathway.
INTRODUCTION
Carbamylation is a spontaneous, non-enzymatic reaction of protein modification by cyanate derived from urea, which is normally present in human plasma and is elevated in uremic patients (27) . Chronic kidney disease in humans is associated with a several times increased risk of developing cardiovascular diseases because of the accelerated atherosclerosis (12, 32, 47). The mechanism of uremia-induced atherosclerosis is not quite understood. We have previously shown that carbamylated low density lipoprotein (cLDL) induces injury or dysfunction of endothelial cells and is present in human plasma in high quantity (2, 36, 37) . Our recent observation that cLDL induces cell death of human coronary artery endothelial cells in vitro provided support to this hypothesis (38).
It is commonly accepted that modified LDLs are important for early atherosclerosis initiation and progression (39, 43). Endothelial dysfunction is often considered as one of the early predominant stages in atherosclerosis development (13). Oxidized LDL (oxLDL), the most intensively studied modified LDL, has been shown to induce endothelial cell death in vitro (31). The cytotoxic effect of oxLDL is often associated with cell proliferation (16). The combination of cell proliferation and cell death resulted in the high turnover of vascular endothelial cells, which is the important characteristic of atherosclerosis (25). Proliferating cells were found to be more sensitive to injury caused by oxLDL (3) . Expectedly, both the proliferating and dead endothelial cells can be observed in early apoptotic lesions (35).
The ability of cLDL to induce proliferation and hence modulate the damage of endothelial cells had not been previously examined. In the current study, we analyzed the proliferative effect of cLDL on human coronary artery endothelial cells (HCAECs) in 8 Statistical analysis. Results were expressed as mean ± standard error of mean (M±SEM). Statistical analysis was performed with ANOVA and Student's t test. Multiple comparisons were performed by t-test with the Bonferoni adjustment. A value of P<0.05 was considered significant.
RESULTS
Induction of endothelial cell proliferation by cLDL. We tested the ability of cLDL to affect BrdU incorporation in a wide range of concentrations (1-400 µg/ml). This range included concentrations of 6.25-12.5 µg/ml and 200 µg/ml, which has been described to induce proliferation and cytotoxicity of oxLDL in vitro (16, 19) . Our data showed that the BrdU incorporation induced by cLDL was higher than nLDL ( Figure 1 ). As shown in the Figure, at both low and high concentrations of cLDL two elevations of BrdU incorporation were observed. The first one was at 2-h incubation and another was at the last time point of 24 h. Incubation beyond 24 h was not used, because it was associated with significant cell death. The 2-h peak of BrdU incorporation was higher than the 24-h elevation, reaching 280%, 370% and 610% above non-treated controls at concentrations of 6.25, 12.5, and 200 µg/ml cLDL, respectively. At 24 h, the BrdU incorporation reached 170%, 280% and 430% at the same cLDL concentrations, respectively.
To determine whether cLDL affects the cell cycle, the cells treated with cLDL or nLDL were subjected to cell cycle analysis by FACS (Figure 2 ). This experiment showed that the cell cycle of cLDL-treated cells was significantly changed by increasing the number 9 of cells in S-phase after both 2-h and 24-h impacts with low (6.25 µg/ml) or high (200 µg/ml) cLDL concentrations confirming that increased BrdU incorporation was associated with scheduled DNA synthesis. Cells treated with 200 µg/ml of cLDL had pre-G1 peak (G0 or so-called apoptotic peak), which was resulted from DNA fragmentation and cell death.
Our data showed that the BrdU incorporation induced by nLDL and cLDL was dosedependent ( Figures 3A and 3B ). After the 2-h impact, the BrdU incorporation induced by cLDL was approximately 2 to 3 times higher than the proliferation induced by nLDL. The 24-h incubation was associated with a ~50% increase of the BrdU incorporation rate above nLDL.
Association of the cLDL-induced HCAEC proliferation with cell death. To study whether proliferation of cLDL-treated endothelial cells is associated cell death, the cytotoxicity of cLDL was measured using the LDH release assay. This experiment revealed that the cell proliferation was accompanied by cell death both at short and long incubations with cLDL ( Figures 3C and 3D) . The difference between the 2-h and 24-h impact proliferation was that at 2 h, cell death induced by cLDL was only 30% higher than that induced by nLDL, while at 24 h, it was 2-fold higher. Thus, the short incubation of the endothelial cells with cLDL was associated mainly with proliferation, whereas the prolonged exposure to cLDL was predominantly associated with cell death.
In order to independently assess the induction of cell death, we have used the TUNEL assay. This assay showed that cLDL impact induced much more apoptotic cell death then the vehicle or nLDL ( Figure 4A ), thus confirming the LDH release results above.
There were several reports that serum and its components protect endothelial cells from the injury caused by modified LDLs (7, 29) . To determine whether cLDL may cause cell death in the presence of serum, endothelial cells were treated with cLDL in complete medium supplemented with serum (5%). Although cells seemed to be more protected compared to the treatment in serum-free medium, we found that cLDL maintains its ability to cause cell death even in the presence of serum ( Figure 4B ).
We further analyzed whether cLDL induced proliferation and death take place in the same endothelial cells, and if there may be a link between these two processes. For this, immunostaining for PCNA or Ki-67, the commonly used markers of cell proliferation, and TUNEL labeling, the marker of apoptosis, were applied. HCAECs were treated with 200 µg/ml cLDL or oxLDL for 24 h, and double-stained for PCNA or and TUNEL. This approach showed that nuclear overexpression of PCNA and Ki-67 induced by cLDL was often associated with apoptosis detected by TUNEL ( Figure 5A and 5B). Surprisingly, our data showed that the exposure of endothelial cells to 200 µg/ml oxLDL for 24 h resulted in the same effect as cLDL: the proliferation of the cells determined by the PCNA-and Ki-67-positive nuclei was associated with apoptosis.
Although, oxLDL has been previously shown to induce proliferation and death of endothelial cells (16, 19), a possible link between these two processes has not been demonstrated. The TUNEL-positive reaction of vehicle control or nLDL was lower than with the modified LDLs and did not correlate with either PCNA or Ki-67 immunostaining.
Similar experiment with treatment of endothelial cells in complete medium containing 5% serum showed that nuclear co-localization of the markers of proliferation and TUNEL was present in both cLDL-and oxLDL-treated cells regardless of the presence of serum in the medium ( Figure 5C and 5D).
Cause-effect relationship between cLDL-or ox-LDL-induced endothelial cell proliferation and cell death. Since the early peak of BrdU incorporation preceded cell death, we hypothesized that conditions of DNA synthesis may sensitize HCAECs to further cytotoxic cLDL or oxLDL impact, and thus the first 2-h peak of proliferation may contribute to the 24-h cell death. Such a phenomenon, called "mitotic cell death" has been described in several other in vitro models, including human endothelial cells (14, 18). To study the cause-effect relationships between cLDL/oxLDL-induced proliferation and cell death, the proliferation was inhibited by aphidicolin and cell death was measured by LDH release. Aphidicolin, a DNA polymerase alpha inhibitor, was chosen because of its ability to specifically inhibit DNA synthesis and arrest cells in G1/S or early S phase (11, 24).
High concentrations of aphidicolin have been described to produce a cytotoxic effect (40). Therefore, prior to the experiment, the application of aphidicolin to HCAECs was tested at several concentrations between 0 and 20 µg/ml to choose the concentration which would inhibit proliferation without any cytotoxic effect. The data presented in Figure 6 showed that at 1 µg/ml, aphidicolin inhibited the proliferation of HCAECs (not treated with LDLs) to 8% of the control. Since 1 µg/ml aphidicolin did not have significant cytotoxicity as measured by LDH release in comparison with the control, this concentration was chosen for further experiments.
We observed that the presence of aphidicolin was cytoprotective against the cLDL injury ( Figure 7) . OxLDL-induced cell death was also prevented with aphidicolin. Therefore, this approach showed that the inhibition of proliferation and arrest of cells at the G1/S phase caused significant decrease of endothelial cell death induced by cLDL.
We next examined whether the arrest of the cells at G1/S by aphidicolin at the moment of cLDL impact would affect the overall cell survival and growth by protecting proliferating cells from injury in a long-term experiment. Our data suggested that despite the short-term impact and quick change of conditions to normal, cell death occurred in the samples treated with cLDL, but not with vehicle-or nLDL-treated cells (Figure 8 ).
Again, treatment with oxLDL had a very similar effect on endothelial cell multiplication. Because several protein kinases and in particular MAPK are involved in many events during endothelial cell proliferation (33, 42, 46), we hypothesized that MAPK pathway may be involved in cause-effect relationship between proliferation and cell death induced by cLDL or oxLDL. In our experiments, cLDL induced significant activation of ERK1/2 at 2, 6 and 12-h points, however there was no activation found at the 24-h point ( Figure 9A ). Similarly to cLDL, oxLDL also caused significant activation of ERK1/2, however phosphorylation of ERK1/2 was observed at all time points. Both cLDL-and oxLDL-induced phosphorylation of JNK/SAPK occurred only at the late time points ( Figure 9B ). MAPK p38 was not activated during the entire treatment course, and the total level of all mentioned proteins was not changed (data not shown). To determine the role of the described changes in cell proliferation and death, U0126, the MEK1/2 inhibitor, and SP600125, the inhibitor of JNK, were applied. The doses of these compounds were elaborated in separate experiments ( Figures 10A and 10B ). Similar to aphidicolin, the inhibition of ERK1/2 phosphorylation led to the significant 2-fold depression of BrdU incorporation ( Figure 11A ) and protected cells from death induced by both cLDL and oxLDL ( Figure 11B ). At the same time, the inhibition of JNK did not affect the proliferation and had an insignificant rescue effect.
DISCUSSION
Both cLDL and oxLDL were shown to be elevated in blood of the patients with chronic kidney disease (2, 23), and have pro-atherogenic properties including cytotoxicity toward endothelial cells (38, 48). Oxidized LDL has been reported to cause endothelial proliferation (16, 19). By using three approaches, which included BrdU incorporation, FACS (S-phase) analysis and cell multiplication, we have demonstrated for the first time that cLDL induces the dose-dependent proliferation of endothelial cells in vitro. We have identified two elevations of cell proliferation induced by cLDL to higher levels then nLDL.
Interestingly, similar elevations were dose-dependent and were observed at high (200 µg/ml) and quite low (6.25 µg/ml) concentrations of cLDL. Recently, we showed that the cLDL concentration in human sera deviates from 0.4 to over 900 µg/ml (2), which makes cLDL concentrations used in the present study relevant to physiological processes in humans. Because of cell death, it was impossible to detect the activation of proliferation and multiplication of the endothelial cells after long exposure to cLDL.
Similar observation was made in another study that used oxLDL (8).
The proliferation after both short and long term incubation with cLDL was associated with cell death detected by LDH release and TUNEL. The oxidatively modified LDL has a dual effect on endothelial cells in vitro, similar to the one observed by us with cLDL (16, 19). The fact that both proliferation and cell death may relate to each other and occur in the same cell has not been previously described. PCNA and Ki-67 were chosen because they are established markers of cell proliferation and have low levels of degradation (21, 45). Thus we expected both of them to remain in the nuclei while proliferation-mediated cell death occurs. These experiments showed that proliferation and subsequent death may occur in the same cell, not just be present in different subpopulations of cells. Because oxLDL showed a similar to cLDL pattern of the staining, it is suggested that both cLDL and oxLDL may at least partially utilize a universal pathway. Such a similarity between the pathways of several other modified LDLs has been previously reported (4, 41).
We observed that the endothelial cell proliferation was associated with death while Sphase arrest by aphidicolin led to cell rescue from modified LDL-induced injury.
Furthermore, a short course of endothelial cell treatment with cLDL or oxLDL followed by a change of media back to normal caused profound cell death at 72 h after impact.
However the pretreatment of endothelial cells with aphidicolin was protective from cLDL-or oxLDL-induced cell death. To the best of our knowledge, this phenomenon was not described with any of the modified LDLs. These data may suggest that cLDL and oxLDL induce fast and irreversible activation of the mechanisms leading to simultaneous cell proliferation and cell death.
We can speculate that cLDL and oxLDL act by stimulating proliferation and inducing a mitogenic effect, which results in mitotic cell death. The latter has been reported to occur due to inappropriate stimuli for cells to proliferate (1, 10) . A recent study by Zetlet 
